Remove topics controlled-substances
article thumbnail

Overview of the S. 3 landscape on patenting biotechnology inventions in India

SpicyIP

Unlike small molecule drugs, biologics are large and complex substances. For product-of-nature subject matter, the primary restrictions under Section 3 are: Section 3(c): The mere discovery of a scientific principle or the formulation of an abstract theory or discovery of any living thing or non-living substance occurring in nature.

article thumbnail

Symposium Spotlight: The Session Overview and the Keynote Speaker

LexBlog IP

As the country slowly addresses and learns to control the prevalence and spread of COVID-19, conversations that were put on hold during the pandemic re-emerge with vigor and debate, including sustainability. Keynote Speaker. Francisco Reyes. ● Consultant to the World Bank. in Law from the University of Tilburg.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Patents & the Magical World of Psychedelics

IPilogue

Psilocybin, an active compound in what is commonly known as “magic mushrooms”, is currently listed under Schedule III of Canada’s Controlled Drugs and Substances Act. The recent trends in psychiatry point to an ever-increasing interest in the role that psychedelic compounds, namely psilocybin, can play in treating these conditions.

Patent 59
article thumbnail

IP and Cannabis: The Current Landscape

Fish & Richardson Trademark & Copyright Thoughts

ii] While marijuana remains a Schedule I controlled substance under federal law, a majority of states have legalized consumption of certain cannabis products under certain conditions. Until 2018, cannabis in almost all of its forms was regulated as a Schedule I controlled substance – the same category used for heroin and LSD.

IP 52
article thumbnail

Journey Through “Augusts” on SpicyIP (2005 – Present)

SpicyIP

He wrote detailed posts on this topic later here and here. Talking about this topic, the issue of Judicial Recusals also shouldn’t be left untouched – an issue that has been the heart of several IP controversies, notably the Novartis dispute. The results revealed that the Ministry of Home Affairs had no source or backing of the data.

IP 105
article thumbnail

What CannI Say? Litigating Cannabis Patents In District Court

LexBlog IP

The authors will be following up on this topic with an article analyzing the reasoning once we have more fully reviewed the transcript. However, the authors observe that the current case law may change if/when cannabis is no longer a Schedule I controlled substance. . § 863 (d)(1)-(15) listing per se drug paraphernalia).

article thumbnail

SpicyIP Weekly Review (February 26- March 3)

SpicyIP

Controller Gen of Patents: The DHC’s Dilemma of Identifying the Method of Treatment under Section 3(i) of the Patent Act In the context of Section 3(i), the DHC recently clarified that a ‘method of treatment’ is distinct from a ‘method of producing a substance’ that can later be used in the treatment.